In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales
Abstract
Ceftibuten/VNRX-7145 is a cephalosporin/boronate β-lactamase inhibitor combination under development as an oral treatment for complicated urinary tract infections caused by Enterobacterales producing serine β-lactamases (Ambler class A, C, and D). In vivo , VNRX-7145 (VNRX-5236 etzadroxil) is cleaved to the active inhibitor, VNRX-5236. We assessed the in vitro activity of ceftibuten/VNRX-5236 against 1,066 urinary isolates of Enterobacterales from a 2014–2016 global culture collection.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 18, 2022
- Source ID
- 10.1128/aac.01304-21
Entities
People
- Daniel F. Sahm
- James A. Karlowsky
- Meredith Hackel
Organizations
- International Hologram Manufacturers Association
- United States Department of Health and Human Services
- University of Manitoba